Search

Search Constraints

You searched for: Author/Creator Steel, Alan

Search Results

5. Comparative effectiveness of antitumour necrosis factor agents and vedolizumab in ulcerative colitis. Issue 6 (June 2019)

6. Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study. (7th April 2022)

7. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study. (February 2022)

8. Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study. (February 2023)

9. P201 Efficacy and safety of switching from intravenous to subcutaneous IFX (CT-P13): a multi-centre cohort study. (19th June 2022)